-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Benzinga·03/09/2026 16:24:01
Listen to the news
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.